4.86
0.05 (1.04%)
| Previous Close | 4.81 |
| Volume | 139,272 |
| Price / Earnings (Forward) | 19.53 |
| Price / Sales | 2.02 |
| Price / Book | 3.25 |
| 52 Weeks Range |
| Profit Margin | 11.40% |
| Operating Margin (TTM) | 9.35% |
| Diluted EPS (TTM) | 0.270 |
| Quarterly Revenue Growth (YOY) | 4.10% |
| Quarterly Earnings Growth (YOY) | -24.20% |
| Total Debt/Equity (MRQ) | 9.20% |
| Current Ratio (MRQ) | 4.70 |
| Operating Cash Flow (TTM) | 65.52 M |
| Levered Free Cash Flow (TTM) | 53.10 M |
| Return on Assets (TTM) | 13.80% |
| Return on Equity (TTM) | 22.29% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | MiMedx Group, Inc | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 2.0 |
| Average | 1.50 |
|
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.71% |
| % Held by Institutions | 70.12% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Essex Woodlands Management, Inc. | 30 Jun 2026 | 28,195,249 |
| Trigran Investments, Inc. | 30 Jun 2026 | 7,173,770 |
| Nantahala Capital Management, Llc | 30 Jun 2026 | 4,767,552 |
| Paradigm Capital Management Inc/Ny | 30 Jun 2026 | 4,073,100 |
| Punch & Associates Investment Management, Inc. | 30 Jun 2026 | 2,058,089 |
| Cannell Capital Llc | 30 Jun 2026 | 1,870,436 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |